Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Oncolytic virus | 2 |
Monoclonal antibody | 2 |
Colony-stimulating factors | 1 |
Antibody drug conjugate (ADC) | 1 |
Target |
Mechanism CD79B inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date10 Jun 2019 |
Target |
Mechanism PDL1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date18 May 2016 |
Target |
Mechanism Bcl-2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date11 Apr 2016 |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Start Date18 Apr 2024 |
Sponsor / Collaborator |
Start Date01 Apr 2024 |
Sponsor / Collaborator Replimune, Inc. [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Oseltamivir Phosphate ( neuraminidase ) | Influenza, Human More | Approved |
Orlistat ( Lipase ) | Obesity More | Approved |
Epoetin beta ( EPO receptor ) | Anemia More | Approved |
Calcitriol ( VDR ) | Vitamin D Deficiency More | Approved |
Obinutuzumab ( CD20 ) | Lupus Nephritis More | Phase 3 |